Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma.
暂无分享,去创建一个
[1] E. Perez,et al. Future options with trastuzumab for primary systemic and adjuvant therapy. , 2004, Seminars in oncology.
[2] Lajos Pusztai,et al. Targeted Therapy in Breast Cancer , 2004, Molecular & Cellular Proteomics.
[3] S. Franco,et al. Clinical Experience with Trastuzumab (Herceptin) , 2003, The breast journal.
[4] M. Dowsett,et al. Current Perspectives on HER2 Testing: A Review of National Testing Guidelines , 2003, Modern Pathology.
[5] O. Dietze,et al. Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma , 2002, Laboratory Investigation.
[6] Takashi Suzuki,et al. Chromogenic in situ hybridization analysis of HER‐2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (Herceptin®) therapy , 2001, Pathology international.
[7] Caroline Lohrisch,et al. The Predictive Value of HER2 in Breast Cancer , 2001, Oncology.
[8] H A Lehr,et al. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. , 2001, American journal of clinical pathology.
[9] I. Andrulis,et al. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. , 2001, American journal of clinical pathology.
[10] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[11] R. Simon,et al. Comparative methodological analysis of erbB‐2/HER‐2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use , 2000, Histopathology.
[12] D. Larsimont,et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. , 2000, The American journal of pathology.
[13] D. Slamon,et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Piccart,et al. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] U. Lehmann,et al. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. , 2000, The American journal of pathology.
[16] I. Bièche,et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. , 1999, Clinical chemistry.
[17] D. Treré,et al. c‐erbB‐2 over‐expression in amplified and non‐amplified breast carcinoma samples , 1999, International journal of cancer.
[18] F. Révillion,et al. ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.
[19] F. Révillion,et al. Quantification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR. , 1997, Clinical chemistry.
[20] D. Slamon,et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Richards,et al. EGF-Related Peptides and Their Receptors in Mammary Gland Development , 1997, Journal of Mammary Gland Biology and Neoplasia.
[22] E. Gelmann,et al. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. , 1994, British Journal of Cancer.
[23] S. Steinberg,et al. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. , 1989, Cancer research.
[24] P. Quirke,et al. Pattern of expression of c-erbB-2 oncoprotein in human fetuses. , 1989, British Journal of Cancer.
[25] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[26] G. Riou,et al. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. , 1988, Oncogene research.